Tripterygium glycosides for safely controlling disease activity in systemic lupus erythematosus: a systematic review with meta-analysis and trial sequential analysis
Background: Tripterygium glycosides have been used to treat systemic lupus erythematosus (SLE) for a long time, showing the effects of immune regulation. We aimed to evaluate the benefits and risks of Tripterygium Glycosides Tablets (TGT) for patients with SLE.Methods: We searched electronic databas...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1207385/full |
| _version_ | 1827877280873971712 |
|---|---|
| author | Yifan Chen Liuding Wang Nannan Li Caiyun Zhou |
| author_facet | Yifan Chen Liuding Wang Nannan Li Caiyun Zhou |
| author_sort | Yifan Chen |
| collection | DOAJ |
| description | Background: Tripterygium glycosides have been used to treat systemic lupus erythematosus (SLE) for a long time, showing the effects of immune regulation. We aimed to evaluate the benefits and risks of Tripterygium Glycosides Tablets (TGT) for patients with SLE.Methods: We searched electronic databases and clinical trial registries for relevant randomized controlled trials (RCTs). We identified eligible RCTs and assessed risk of bias. We conducted a meta-analysis to estimate the pooled effects. The Trial Sequential Analysis (TSA) 0.9.5.10 software was used to verify the reliability of the results.Results: Eight RCTs encompassing 538 patients with SLE were included. TGT combined with conventional treatments (CTs) was superior to CTs alone in reducing lupus activity (MD = −1.66, 95% CI = −2.07 to −1.26, p < 0.00001, low-certainty evidence) and improving overall response rate (ORR) (RR = 1.21, 95% CI = 1.11 to 1.32, p < 0.0001, moderate-certainty evidence). The robustness of the results was confirmed by TSA. Regarding safety, there was no statistical difference in the overall incidence of adverse reactions between the two groups.Conclusion: In patients with SLE, TGT might safely reduce disease activity. However, further high-quality studies are needed to firmly establish the clinical efficacy of TGT.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022300474; Identifier: CRD42022300474. |
| first_indexed | 2024-03-12T17:35:13Z |
| format | Article |
| id | doaj.art-08fc0f3d745c4347a8b06bed1c6e664c |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-12T17:35:13Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-08fc0f3d745c4347a8b06bed1c6e664c2023-08-04T11:51:08ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-08-011410.3389/fphar.2023.12073851207385Tripterygium glycosides for safely controlling disease activity in systemic lupus erythematosus: a systematic review with meta-analysis and trial sequential analysisYifan ChenLiuding WangNannan LiCaiyun ZhouBackground: Tripterygium glycosides have been used to treat systemic lupus erythematosus (SLE) for a long time, showing the effects of immune regulation. We aimed to evaluate the benefits and risks of Tripterygium Glycosides Tablets (TGT) for patients with SLE.Methods: We searched electronic databases and clinical trial registries for relevant randomized controlled trials (RCTs). We identified eligible RCTs and assessed risk of bias. We conducted a meta-analysis to estimate the pooled effects. The Trial Sequential Analysis (TSA) 0.9.5.10 software was used to verify the reliability of the results.Results: Eight RCTs encompassing 538 patients with SLE were included. TGT combined with conventional treatments (CTs) was superior to CTs alone in reducing lupus activity (MD = −1.66, 95% CI = −2.07 to −1.26, p < 0.00001, low-certainty evidence) and improving overall response rate (ORR) (RR = 1.21, 95% CI = 1.11 to 1.32, p < 0.0001, moderate-certainty evidence). The robustness of the results was confirmed by TSA. Regarding safety, there was no statistical difference in the overall incidence of adverse reactions between the two groups.Conclusion: In patients with SLE, TGT might safely reduce disease activity. However, further high-quality studies are needed to firmly establish the clinical efficacy of TGT.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022300474; Identifier: CRD42022300474.https://www.frontiersin.org/articles/10.3389/fphar.2023.1207385/fulltripterygium glycosidessystemic lupus erythematosuslupus activitysystematic reviewmeta-analysis |
| spellingShingle | Yifan Chen Liuding Wang Nannan Li Caiyun Zhou Tripterygium glycosides for safely controlling disease activity in systemic lupus erythematosus: a systematic review with meta-analysis and trial sequential analysis Frontiers in Pharmacology tripterygium glycosides systemic lupus erythematosus lupus activity systematic review meta-analysis |
| title | Tripterygium glycosides for safely controlling disease activity in systemic lupus erythematosus: a systematic review with meta-analysis and trial sequential analysis |
| title_full | Tripterygium glycosides for safely controlling disease activity in systemic lupus erythematosus: a systematic review with meta-analysis and trial sequential analysis |
| title_fullStr | Tripterygium glycosides for safely controlling disease activity in systemic lupus erythematosus: a systematic review with meta-analysis and trial sequential analysis |
| title_full_unstemmed | Tripterygium glycosides for safely controlling disease activity in systemic lupus erythematosus: a systematic review with meta-analysis and trial sequential analysis |
| title_short | Tripterygium glycosides for safely controlling disease activity in systemic lupus erythematosus: a systematic review with meta-analysis and trial sequential analysis |
| title_sort | tripterygium glycosides for safely controlling disease activity in systemic lupus erythematosus a systematic review with meta analysis and trial sequential analysis |
| topic | tripterygium glycosides systemic lupus erythematosus lupus activity systematic review meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1207385/full |
| work_keys_str_mv | AT yifanchen tripterygiumglycosidesforsafelycontrollingdiseaseactivityinsystemiclupuserythematosusasystematicreviewwithmetaanalysisandtrialsequentialanalysis AT liudingwang tripterygiumglycosidesforsafelycontrollingdiseaseactivityinsystemiclupuserythematosusasystematicreviewwithmetaanalysisandtrialsequentialanalysis AT nannanli tripterygiumglycosidesforsafelycontrollingdiseaseactivityinsystemiclupuserythematosusasystematicreviewwithmetaanalysisandtrialsequentialanalysis AT caiyunzhou tripterygiumglycosidesforsafelycontrollingdiseaseactivityinsystemiclupuserythematosusasystematicreviewwithmetaanalysisandtrialsequentialanalysis |